Source comparison
BPC-157 Studied Sports Injury — Comparison Across Injury Types
The comparison table below synthesises findings from published BPC-157 studied sports injury research across different tissue types, highlighting which injuries show the most consistent evidence for accelerated recovery. Achilles Tendon Rupture Rat transection
This comparison does not assign a generated winner or score.
- The comparison table below synthesises findings from published BPC-157 studied sports injury research across different tissue types, highlighting which injuries show the most consistent evidence for accelerated recovery.
- Achilles Tendon Rupture
- Rat transection model
- 72% faster tensile strength recovery at 14 days
- Enhanced collagen type I deposition, increased fibroblast proliferation
- No human RCTs; case reports only
- Medial Collateral Ligament Tear
- Rat MCL transection
- 58% improvement in structural integrity at 21 days
- VEGF-mediated angiogenesis, FAK-paxillin pathway activation
- Unpublished human observational data
- Muscle Laceration (Gastrocnemius)
- Rat surgical laceration
- 43% reduction in scar tissue formation, 31% faster return of contractile function
- Modulation of TGF-β1 expression, reduced fibrosis
- No controlled human trials
- Tendon-to-Bone Healing (Rotator Cuff)
- Rabbit supraspinatus repair model
- 2.3× higher load-to-failure at 4 weeks post-op
- Enhanced bone-tendon interface formation, increased Sharpey fibre density
- Human safety data insufficient
- Bone Fracture
- Rat femur fracture model
- 19% faster radiographic union, improved callus mineralisation
- Osteoblast proliferation, enhanced periosteal response
- Preliminary human case series (n=12)
- Assessment
- BPC-157 shows strongest evidence in tendon and ligament models, with consistent improvements in structural outcomes and healing timeline. Muscle injury data suggests reduced fibrosis but smaller magnitude effects. Bone healing evidence is weakest, with modest improvements that may not justify peptide intervention over standard care. Human translation remains speculative. No Phase III trials exist for any indication.